热门资讯> 正文
Rani Therapeutics GAAP每股收益为-0.26美元
2024-08-08 01:31
- Rani Therapeutics press release (NASDAQ:RANI): Q2 GAAP EPS of -$0.26.
- Cash, cash equivalents and marketable securities as of June 30, 2024 totaled $30.9M, compared to $48.5M for the year ended December 31, 2023.
- Shares -2.4%.
More on Rani Therapeutics
- Rani Therapeutics prices securities offering to raise $10 million
- Rani Therapeutics enters into partnership with ProGen for oral obesity treatment
- Seeking Alpha’s Quant Rating on Rani Therapeutics
- Historical earnings data for Rani Therapeutics
- Financial information for Rani Therapeutics
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
